{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:11:12Z","timestamp":1783635072333,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,8,16]],"date-time":"2004-08-16T00:00:00Z","timestamp":1092614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To compare event rates for osteoporotic fractures, cardiovascular events, and breast cancer in postmenopausal women with osteoporosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design:<\/jats:bold>\n                    A prospective, observational study of the placebo group in the double\u2010blind, randomized Multiple Outcomes of Raloxifene Evaluation trial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting:<\/jats:bold>\n                    One hundred eighty clinical research centers in 25 countries.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Participants:<\/jats:bold>\n                    Postmenopausal women (n=2,565, mean age=67) with osteoporosis were given calcium (500\u2003mg\/d) and vitamin D (400\u2013600 IU\/d) supplements.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements:<\/jats:bold>\n                    The occurrence of at least one new fracture, cardiovascular event, or breast cancer diagnosis at 3 years was identified and adjudicated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The occurrence of any fracture was the most common event in these women. In women without prevalent vertebral fractures (n=1,627), the event rates per 1,000 patient\u2010years were 45.4 for any fracture, 15.2 for vertebral fracture, 4.7 for clinical vertebral fracture, 0.9 for hip fracture, 8.3 for any cardiovascular event, and 5.2 for all breast cancer. In women with prevalent vertebral fractures (n=938), the event rates per 1,000 patient\u2010years were 117.4 for any new fracture, 77.1 for new vertebral fracture, 25.7 for clinical vertebral fracture, 5.8 for hip fracture, 15.1 for any cardiovascular event, and 2.6 for all breast cancer. The effect of prevalent fracture status on event rates was not dependent on whether women were older or younger than 65, but women aged 65 and older had a 3.6 times greater occurrence of cardiovascular events than younger women, irrespective of prevalent fracture status.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    These data on the relative incidence of clinically significant skeletal and extra\u2010skeletal outcomes may be useful in choosing an agent for health maintenance for postmenopausal women with osteoporosis.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2004.52420.x","type":"journal-article","created":{"date-parts":[[2004,8,16]],"date-time":"2004-08-16T07:02:37Z","timestamp":1092639757000},"page":"1543-1548","source":"Crossref","is-referenced-by-count":35,"title":["Comparison of Fracture, Cardiovascular Event, and Breast Cancer Rates at 3 Years in Postmenopausal Women with Osteoporosis"],"prefix":"10.1111","volume":"52","author":[{"given":"Stuart L.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D.","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandurang M.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayme","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Leo","family":"Plouffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,16]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"National Osteoporosis Foundation (NOF) [on\u2010line].Available athttp:\/\/www.nof.org\/ Accessed October 21 2003."},{"key":"e_1_2_6_3_2","unstructured":"International Osteoporosis Foundation (IOF) [on\u2010line].Available athttp:\/\/www.osteofound.org\/index.phpAccessed October 21 2003."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb02641.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070075"},{"key":"e_1_2_6_6_2","unstructured":"American Heart Association (AHA) [on\u2010line].Available athttp:\/\/www.americanheart.org\/presenter.jhtml?identifier=1200000 Accessed October 21 2003."},{"key":"e_1_2_6_7_2","unstructured":"American Cancer Society (ACS) [on\u2010line].Available athttp:\/\/www.cancer.org\/docroot\/home\/index.aspAccessed October 21 2003."},{"key":"e_1_2_6_8_2","unstructured":"Imaginis\u2010Breast Cancer Statistics [on\u2010line].Available athttp:\/\/www.imaginis.com\/Accessed October 21 2003."},{"key":"e_1_2_6_9_2","first-page":"1404","article-title":"Bone mineral density and risk of breast cancer in older women","volume":"276","author":"Cauley J","year":"1996","journal-title":"The study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00003"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-85-4-447"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_6_13_2","first-page":"637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene","volume":"282","author":"Ettinger B","year":"1999","journal-title":"Results from a 3-year randomized-clinical trial"},{"key":"e_1_2_6_14_2","first-page":"125","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene","volume":"65","author":"Cauley J","year":"2001","journal-title":"Four-year results from the MORE trial"},{"key":"e_1_2_6_15_2","first-page":"847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women","volume":"287","author":"Barrett\u2010Connor E","year":"2002","journal-title":"Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110716"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1140"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050093"},{"key":"e_1_2_6_19_2","first-page":"2815","article-title":"Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women","volume":"286","author":"Siris ES","year":"2001","journal-title":"Results from the National Osteoporosis Risk Assessment"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-11-919"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.3.320"},{"key":"e_1_2_6_22_2","first-page":"1025","article-title":"Diagnosis and management of osteoporosis in postmenopausal women","volume":"21","author":"Meunier PJ","year":"1999","journal-title":"Clinical guidelines. International Committee for Osteoporosis Clinical Guidelines"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-12-1016"},{"key":"e_1_2_6_24_2","first-page":"3111","article-title":"Indicators of lifetime estrogen exposure","volume":"19","author":"Lippman ME","year":"2001","journal-title":"Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.2.216"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390110045010"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-12-200012190-00008"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371003"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2004.52420.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2004.52420.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:53:39Z","timestamp":1762192419000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2004.52420.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,16]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1532-5415.2004.52420.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2004.52420.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,16]]}}}